{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:49:55Z","timestamp":1791899395012,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10554-020-02115-w","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T22:03:09Z","timestamp":1609711389000},"page":"1415-1422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-5049","authenticated-orcid":false,"given":"Jie","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman E.","family":"Lepor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1dor","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurn","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Hippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Isquith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Balu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Kedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Americo A.","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Hatsukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"2115_CR1","first-page":"R625","volume":"2018","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. Circulation 139:e1082\u2013e1143","journal-title":"Circulation"},{"key":"2115_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713\u20131722","journal-title":"N Engl J Med"},{"key":"2115_CR3","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379:2097\u20132107","journal-title":"N Engl J Med"},{"key":"2115_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.111.047431","volume":"125","author":"A Arbab-Zadeh","year":"2012","unstructured":"Arbab-Zadeh A, Nakano M, Virmani R, Fuster V (2012) Acute coronary events. Circulation 125:1147\u20131156","journal-title":"Circulation"},{"key":"2115_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jacc.2012.10.054","volume":"61","author":"J Narula","year":"2013","unstructured":"Narula J, Nakano M, Virmani R et al (2013) Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol 61:1041\u20131051","journal-title":"J Am Coll Cardiol"},{"key":"2115_CR6","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1161\/CIRCULATIONAHA.104.528174","volume":"112","author":"JM Cai","year":"2005","unstructured":"Cai JM, Hatsukami TS, Ferguson MS et al (2005) In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 112:3437\u20133444","journal-title":"Circulation"},{"key":"2115_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1148\/radiol.2232010659","volume":"223","author":"BA Wasserman","year":"2002","unstructured":"Wasserman BA, Smith WI, Trout HH, Cannon RO, Balaban RS, Arai AE (2002) Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging\u2013initial results. Radiology 223:566\u2013573","journal-title":"Radiology"},{"key":"2115_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejvs.2004.05.001","volume":"28","author":"RA Trivedi","year":"2004","unstructured":"Trivedi RA, U-King-Im J, Graves MJ et al (2004) Multi-sequence in vivo MRI can quantify fibrous cap and lipid core components in human carotid atherosclerotic plaques. Eur J Vasc Endovasc Surg 28:207\u2013213","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2115_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1148\/radiol.2412051336","volume":"241","author":"WS Kerwin","year":"2006","unstructured":"Kerwin WS, O\u2019Brien KD, Ferguson MS, Polissar N, Hatsukami TS, Yuan C (2006) Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241:459\u2013468","journal-title":"Radiology"},{"key":"2115_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1148\/radiol.12120499","volume":"266","author":"ME Gaens","year":"2013","unstructured":"Gaens ME, Backes WH, Rozel S et al (2013) Dynamic contrast-enhanced MR imaging of carotid atherosclerotic plaque: model selection, reproducibility, and validation. Radiology 266:271\u2013279","journal-title":"Radiology"},{"key":"2115_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCIMAGING.114.002113","volume":"7","author":"VR Taqueti","year":"2014","unstructured":"Taqueti VR, Di Carli MF, Jerosch-Herold M et al (2014) Increased microvascularization and vessel permeability associate with active inflammation in human atheromata. Circ Cardiovasc Imaging 7:920\u2013929","journal-title":"Circ Cardiovasc Imaging"},{"key":"2115_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1148\/radiol.14131020","volume":"271","author":"AE Zavodni","year":"2014","unstructured":"Zavodni AE, Wasserman BA, McClelland RL et al (2014) Carotid artery plaque morphology and composition in relation to incident cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA). Radiology 271:381\u2013389","journal-title":"Radiology"},{"key":"2115_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jcmg.2016.06.017","volume":"10","author":"J Sun","year":"2017","unstructured":"Sun J, Zhao XQ, Balu N et al (2017) Carotid plaque lipid content and fibrous cap status predict systemic CV outcomes: the MRI substudy in AIM-HIGH. JACC Cardiovasc Imaging 10:241\u2013249","journal-title":"JACC Cardiovasc Imaging"},{"key":"2115_CR14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jacc.2003.09.063","volume":"43","author":"O Honda","year":"2004","unstructured":"Honda O, Sugiyama S, Kugiyama K et al (2004) Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol 43:1177\u20131184","journal-title":"J Am Coll Cardiol"},{"key":"2115_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00701-019-03825-4","volume":"161","author":"A Ogata","year":"2019","unstructured":"Ogata A, Oho K, Matsumoto N et al (2019) Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab. Acta Neurochir (Wien) 161:597\u2013600","journal-title":"Acta Neurochir (Wien)"},{"key":"2115_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1148\/radiol.13121702","volume":"268","author":"J Sun","year":"2013","unstructured":"Sun J, Balu N, Hippe DS et al (2013) Subclinical carotid atherosclerosis: short-term natural history of lipid-rich necrotic core\u2014a multicenter study with MR imaging. Radiology 268:61\u201368","journal-title":"Radiology"},{"key":"2115_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ahj.2007.11.018","volume":"155","author":"HR Underhill","year":"2008","unstructured":"Underhill HR, Yuan C, Zhao XQ et al (2008) Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 155:581\u2013584","journal-title":"Am Heart J"},{"key":"2115_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10554-014-0532-7","volume":"31","author":"J Sun","year":"2015","unstructured":"Sun J, Zhao XQ, Balu N et al (2015) Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study. Int J Cardiovasc Imaging 31:95\u2013103","journal-title":"Int J Cardiovasc Imaging"},{"key":"2115_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/rmr.0b013e3181598d9d","volume":"18","author":"WS Kerwin","year":"2007","unstructured":"Kerwin WS, Xu D, Liu F et al (2007) Magnetic resonance imaging of carotid atherosclerosis: plaque analysis. Top Magn Reson Imaging 18:371\u2013378","journal-title":"Top Magn Reson Imaging"},{"key":"2115_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jmri.20599","volume":"24","author":"N Takaya","year":"2006","unstructured":"Takaya N, Cai JM, Ferguson MS et al (2006) Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J Magn Reson Imaging 24:203\u2013210","journal-title":"J Magn Reson Imaging"},{"key":"2115_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1148\/radiol.11101264","volume":"260","author":"L Dong","year":"2011","unstructured":"Dong L, Kerwin WS, Chen H et al (2011) Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum-evaluation by using dynamic contrast-enhanced MR imaging. Radiology 260:224\u2013231","journal-title":"Radiology"},{"key":"2115_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mrm.21532","volume":"59","author":"WS Kerwin","year":"2008","unstructured":"Kerwin WS, Oikawa M, Yuan C, Jarvik GP, Hatsukami TS (2008) MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn Reson Med 59:507\u2013514","journal-title":"Magn Reson Med"},{"key":"2115_CR23","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1161\/STROKEAHA.113.002551","volume":"44","author":"A Gupta","year":"2013","unstructured":"Gupta A, Baradaran H, Schweitzer AD et al (2013) Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke 44:3071\u20133077","journal-title":"Stroke"},{"key":"2115_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jcmg.2011.06.013","volume":"4","author":"XQ Zhao","year":"2011","unstructured":"Zhao XQ, Dong L, Hatsukami T et al (2011) MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. J Am Coll Cardiol Img 4:977\u2013986","journal-title":"J Am Coll Cardiol Img"},{"key":"2115_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neurad.2016.12.004","volume":"44","author":"W Brinjikji","year":"2017","unstructured":"Brinjikji W, Lehman VT, Kallmes DF et al (2017) The effects of statin therapy on carotid plaque composition and volume: a systematic review and meta-analysis. J Neuroradiol 44:234\u2013240","journal-title":"J Neuroradiol"},{"key":"2115_CR26","doi-asserted-by":"crossref","unstructured":"Hoogeveen RM, Opstal TSJ, Kaiser Y et al (2019) PCSK9 Antibody alirocumab attenuates arterial wall inflammation without changes in circulating inflammatory markers. JACC Cardiovasc Imaging 12:2571\u20132573","DOI":"10.1016\/j.jcmg.2019.06.022"},{"key":"2115_CR27","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.jcmg.2019.09.024","volume":"12","author":"C Vlachopoulos","year":"2019","unstructured":"Vlachopoulos C, Koutagiar I, Skoumas I et al (2019) Long-term administration of proprotein convertase subtilisin\/kexin type 9 inhibitors reduces arterial FDG uptake. JACC Cardiovasc Imaging 12:2573\u20132574","journal-title":"JACC Cardiovasc Imaging"},{"key":"2115_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12916-015-0459-4","volume":"13","author":"M Banach","year":"2015","unstructured":"Banach M, Serban C, Sahebkar A et al (2015) Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med 13:229","journal-title":"Bmc Med"},{"key":"2115_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ehjci\/jey012","volume":"19","author":"L Andelius","year":"2018","unstructured":"Andelius L, Mortensen MB, Norgaard BL, Abdulla J (2018) Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging 19:850\u2013858","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2115_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jacc.2013.03.058","volume":"62","author":"AS Kini","year":"2013","unstructured":"Kini AS, Baber U, Kovacic JC et al (2013) Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol 62:21\u201329","journal-title":"J Am Coll Cardiol"},{"key":"2115_CR31","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/01.CIR.103.7.926","volume":"103","author":"M Crisby","year":"2001","unstructured":"Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques\u2014implications for plaque stabilization. Circulation 103:926\u2013933","journal-title":"Circulation"},{"key":"2115_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H et al (2015) Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66:495\u2013507","journal-title":"J Am Coll Cardiol"},{"key":"2115_CR33","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T et al (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316:2373\u20132384","journal-title":"JAMA"},{"key":"2115_CR34","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","volume":"72","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Puri R, Anderson T et al (2018) Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol 72:2012\u20132021","journal-title":"J Am Coll Cardiol"},{"key":"2115_CR35","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","volume":"40","author":"LCA Stiekema","year":"2019","unstructured":"Stiekema LCA, Stroes ESG, Verweij SL et al (2019) Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment. Eur Heart J 40:2775\u20132781","journal-title":"Eur Heart J"},{"key":"2115_CR36","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s00259-013-2518-4","volume":"40","author":"C Calcagno","year":"2013","unstructured":"Calcagno C, Ramachandran S, Izquierdo-Garcia D et al (2013) The complementary roles of dynamic contrast-enhanced MRI and F-fluorodeoxyglucose PET\/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging 40:1884\u20131893","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2115_CR37","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1161\/STROKEAHA.113.003140","volume":"44","author":"MTB Truijman","year":"2013","unstructured":"Truijman MTB, Kwee RM, van Hoof RHM et al (2013) Combined 18F-FDG PET-CT and DCE-MRI to assess inflammation and microvascularization in atherosclerotic plaques. Stroke 44:3568\u20133570","journal-title":"Stroke"},{"key":"2115_CR38","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1161\/STROKEAHA.114.005147","volume":"45","author":"J Wang","year":"2014","unstructured":"Wang J, Liu H, Sun J et al (2014) Varying correlation between 18F-fluorodeoxyglucose positron emission tomography and dynamic contrast-enhanced MRI in carotid atherosclerosis: implications for plaque inflammation. Stroke 45:1842\u20131845","journal-title":"Stroke"},{"key":"2115_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jcmg.2016.06.013","volume":"10","author":"JT Chai","year":"2017","unstructured":"Chai JT, Biasiolli L, Li L et al (2017) Quantification of lipid-rich core in carotid atherosclerosis using MRI T2 mapping\u2014relation to clinical presentation. J Am Coll Cardiol Img 10:747\u2013756","journal-title":"J Am Coll Cardiol Img"},{"key":"2115_CR40","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1002\/mrm.27361","volume":"80","author":"H Qi","year":"2018","unstructured":"Qi H, Sun J, Qiao H et al (2018) Simultaneous T1 and T2 mapping of the carotid plaque (SIMPLE) with T2 and inversion recovery prepared 3D radial imaging. Magn Reson Med 80:2598\u20132608","journal-title":"Magn Reson Med"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-020-02115-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10554-020-02115-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-020-02115-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T05:27:02Z","timestamp":1617773222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10554-020-02115-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2115"],"URL":"https:\/\/doi.org\/10.1007\/s10554-020-02115-w","relation":{},"ISSN":["1569-5794","1573-0743"],"issn-type":[{"value":"1569-5794","type":"print"},{"value":"1573-0743","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Norman E. Lepor: Speakers bureau: Amgen, Sanofi, and Regeneron; Research support: The Medicines Company, Esperion, Amgen, Sanofi, and Regeneron. Daniel S. Hippe: Research support: GE Healthcare, Philips Healthcare, Toshiba America Medical Systems, Siemens Medical Solutions USA. Chun Yuan: Research support: Philips Healthcare. Xue-Qiao Zhao: Research support: Amgen, AstraZeneca. Thomas S. Hatsukami: Research support: Philips Healthcare. Other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All study participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have seen and approved the manuscript being submitted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Approved by the Western Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}